Atul Batra, Additional Professor of Medical Oncology at AIIMS, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in ESMO Annals of Oncology:
“Delighted to share that the full paper of PLANeT trial is now available online in Annals of Oncology.
We demonstrated that doses as low as 50 mg every 6 weeks of pembrolizumab led to an improvement in PCR rates by 13.3% (very similar to KN522).
This can significantly improve access to pembrolizumab in patients with TNBC across the globe.”
Sumanta K. Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared this post, adding:
“Huge congrats to Atul Batra and the stellar team at AIIMS New Delhi on publication of the PLANeT trial (chemo +/- low dose pembro in TNBC) in the Annals of Oncology. A Herculean effort done at an amazing pace, with key implications that could extend across other areas in oncology. Looking fwd to meeting in person in < 1 week!”
Title: A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial – Pembrolizumab Low Dose in Addition to NACT in TNBC]
Authors: A. Arora, H. Bhaskarane, G. Tansir, S. Bakhshi, A. Gogia, A. Kumar, R. Jain, K. Kalra, D. Vishvam, S. Mathur, R. Rathore, S.A. Shamim, E. Dhamija, K. Rangarajan, P. Tanwar, C.P. Prasad, S. Kumar, I. Gupta, K. Mani, A.D. Upadhyay, M.K. Diwakar, P. Vasudeva, N. Verma, S. Agstam, V. Seenu, R. Prashad, V.K. Bansal, A. Dhar, A. Krishna, P. Ranjan, S. Suhani, O. Prakash, K. Kataria, B. Kumar, A. Mishra, J. Sharma, B. Bansal, J. Saikia, S. Bhasker, K.P. Haresh, S. Gupta, S.K. Saini, S. Mallick, A. Batra
Read the Full Article on ESMO Annals of Oncology
More posts featuring Atul Batra.